NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free CMND Stock Alerts $1.14 -0.01 (-0.87%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$1.13▼$1.1850-Day Range$1.08▼$1.5052-Week Range$0.92▼$20.40Volume48,123 shsAverage Volume1.56 million shsMarket Capitalization$1.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Clearmind Medicine alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Clearmind Medicine Stock (NASDAQ:CMND)Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Read More CMND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMND Stock News HeadlinesMay 25, 2024 | americanbankingnews.comClearmind Medicine (NASDAQ:CMND) Trading Up 2.2%May 10, 2024 | globenewswire.comClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductMay 7, 2024 | msn.comWhy Clearmind Medicine Stock Is Moving HigherMay 7, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | globenewswire.comClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 1, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in CanadaApril 30, 2024 | globenewswire.comClearmind Applies to Cease Being a Reporting Issuer in CanadaApril 17, 2024 | msn.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | globenewswire.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 11, 2024 | uk.investing.comClearmind Medicine advances trial for alcohol use disorder treatmentApril 10, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 9, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | globenewswire.comClearmind Medicine CEO Issues Letter to ShareholdersMarch 29, 2024 | uk.investing.comClearmind Medicine files tenth patent for depression treatmentMarch 27, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | globenewswire.comClearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 19, 2024 | globenewswire.comBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | msn.comClearmind Medicine receives nod for delisting of shares from Canadian Securities ExchangeMarch 13, 2024 | globenewswire.comClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | globenewswire.comClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeSee More Headlines Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/28/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMND CUSIPN/A CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-265.38% Return on Assets-121.95% Debt Debt-to-Equity Ratio0.01 Current Ratio1.96 Quick Ratio1.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book0.27Miscellaneous Outstanding Shares1,690,000Free FloatN/AMarket Cap$1.93 million OptionableNot Optionable Beta1.06 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Adi Zuloff-Shani Ph.D. (Age 55)Chief Executive Officer Mr. Alan Mark Rootenberg B.Com. (Age 72)B.Comm, C.A., CPA, Chief Financial Officer Prof. Mark Haden M.S.W. (Age 69)Vice President of Business Development Mr. Gilad BabchukHead of Strategy & CommunicationKey CompetitorsASLAN PharmaceuticalsNASDAQ:ASLNFirst Wave BioPharmaNASDAQ:FWBITrevenaNASDAQ:TRVNLongeveronNASDAQ:LGVNShuttle PharmaceuticalsNASDAQ:SHPHView All Competitors CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed in 2024? Clearmind Medicine's stock was trading at $2.81 on January 1st, 2024. Since then, CMND shares have decreased by 59.4% and is now trading at $1.14. View the best growth stocks for 2024 here. Are investors shorting Clearmind Medicine? Clearmind Medicine saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 242,200 shares, an increase of 50.5% from the April 30th total of 160,900 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 8.3% of the company's stock are short sold. View Clearmind Medicine's Short Interest. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) issued its quarterly earnings results on Monday, March, 18th. The company reported ($0.90) earnings per share (EPS) for the quarter. What ETF holds Clearmind Medicine's stock? AdvisorShares Psychedelics ETF holds 128,641 shares of CMND stock, representing 2.43% of its portfolio. When did Clearmind Medicine's stock split? Clearmind Medicine's stock reverse split on the morning of Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an IPO on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMND) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.